About KromaTiD
KromaTiD is a company based in Fort Collins (United States) founded in 2007. KromaTiD has raised $14.54 million across 13 funding rounds from investors including HHS, Broadoak Capital Partners and NHGRI. KromaTiD offers products and services including KROMASURE™ Platform, KROMASURE™ Screen, KROMASURE™ KBand, KROMASURE™ InSite, and KROMASURE™ PinPoint. KromaTiD operates in a competitive market with competitors including Inflammatix, Agendia, PathogenDX, Affymetrix and InDevR, among others.
- Headquarter Fort Collins, United States
- SectorsHealthcare
- Website kromatid.com
- Social LinkedIn YouTube
- Total Equity Funding$14.54 M (USD)
in 13 rounds
- Latest Funding Round$7.13 M (USD), Series A
Jul 01, 2025
- InvestorsHHS
& 3 more
Products & Services of KromaTiD
KromaTiD offers a comprehensive portfolio of products and services, including KROMASURE™ Platform, KROMASURE™ Screen, KROMASURE™ KBand, KROMASURE™ InSite, and KROMASURE™ PinPoint.
Offers single-cell insights for chromosomal integrity in therapy research
Detects chromosome mutations and structural variants
Provides G-Banding for variant analysis
Visualizes structural variants and transgene inserts
Delivers custom probes for detailed genomic testing
Apps and channels of KromaTiD
its YouTube channel KromaTiD Education has 11 subscribers and 18 videos.
Videos from KromaTiD
The most watched videos on KromaTiD's YouTube channel, KromaTiD Education (11 subscribers). Click a video to play it here.
More on KromaTiD Education.
Funding Insights of KromaTiD
KromaTiD has successfully raised a total of $14.54M across 13 strategic funding rounds. The most recent funding activity was a Series A round of $7.13 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.5M
- Total Rounds 13
- Last Round Series A — $7.1M
- First Round $50,000
(05 Sep 2013)
- Investors Count 4
Latest 10 of 13 funding rounds of KromaTiD with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| 01 Jul 2025 | $7.1M | Series A | – | – | – |
| 17 Jan 2024 | $2.1M | Series A | – | – | – |
| 28 Apr 2021 | $2.0M | Series A | – | Broadoak Capital Partners | – |
| 15 Jan 2021 | $1.6M | Grant | – | – | |
| 04 Aug 2020 | $1.7M | Grant | – | – | |
| 08 Aug 2019 | $1.9M | Series A | – | First Capital Ventures | – |
| 23 Apr 2019 | $900,000 | Grant | – | – | |
| 25 Feb 2019 | $850,000 | Series A | – | – | – |
| 01 Aug 2018 | $893,067 | Grant | – | – | |
| 31 May 2017 | – | Series A | – | – |
4 investors in total: 4 institutional.
Investors in KromaTiD
KromaTiD has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Broadoak Capital Partners and NHGRI.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | firstcapitalventures.com | - | |
Investment banking services are offered in the United States. | 2006 | broadoak.com | Bethesda, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Genomics research and educational resources are provided. | 1988 | genome.gov | Bethesda, United States |
Investor details for KromaTiD
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of KromaTiD
8 people are tracked at KromaTiD (2 in leadership, 6 in board & advisors).
| Name | Role | Group |
|---|---|---|
Andrew Ray | Co-Founder and SAB member | Leadership |
Gordon Link | CFO | Leadership |
Walt Young | Director | Board & advisors |
David Brunel | Director | Board & advisors |
Terry Opgenorth | Director | Board & advisors |
Priya Gogoi | Director | Board & advisors |
Jack Ball | Director | Board & advisors |
James E. Chomas | Director | Board & advisors |
Complete people profiles for KromaTiD
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of KromaTiD
3 dated milestones of KromaTiD across 18 years, from founding to its latest funding, stage changes and deals.
- Founded KromaTiD is founded.
- Funding First funding round of $50K.
- Funding Latest funding round, Series A, of $7.1M.
Competitors of KromaTiD
KromaTiD operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, Agendia, PathogenDX, Affymetrix and InDevR, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.5M | 54 | Provider of diagnostic solutions for systemic infections | |
| agendia.com | 2003 | Irvine, United States | $123.0M | 203 | Genomic diagnostic products for cancer treatment are provided. | |
| pathogendx.com | 2014 | Tucson, United States | $11.6M | 31 | Provider of DNA-based pathogen testing kits | |
| affymetrix.com | 1991 | Santa Clara, United States | – | 721 | Provider of technologies for multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level | |
| indevr.com | 2003 | Boulder, United States | $16.0M | – | Biotherapeutics, vaccines, and diagnostic products are manufactured and developed. | |
| genomedx.com | 2008 | San Diego, United States | $69.7M | 159 | Genomic tests for urologic cancers are developed and commercialized. | |
| sengenics.com | 2008 | Singapore | – | – | Diagnostics and Research using next-generation sequencing, protein and DNA microarray technologies | |
| biocopy.com | 2018 | Basel, Switzerland | – | – | Developer of immunotherapies for tumor and autoimmune diseases |
Detailed competitors of KromaTiD
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kromatid
Complete news archive for KromaTiD
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to KromaTiD
10 companies that operate in the same segment as KromaTiD (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about KromaTiD
KromaTiD was founded in 2007 and raised its 1st funding round 6 years after it was founded.
KromaTiD is headquartered in Fort Collins, United States. It is registered at Fort Collins, Colorado, United States.
KromaTiD is a funded company, having raised a total of $14.54M across 13 funding rounds to date.
Provider of molecular and genetic tests for detection of disease-causing mutations, including inversions and translocations, in a single test. Based on its patented Directional Genomic Hybridization (dGH), KromaTiDs assays generate the sequence, location, and orientation data from single cells, making them ideal for mixed cell population studies. KromaTiDs research products and services help in a deeper understanding of genetic diseases, including cancers and developmental disorders.
KromaTiD's top competitors include Inflammatix, PathogenDX and Agendia.
KromaTiD offers KROMASURE™ Platform, KROMASURE™ Screen, KROMASURE™ KBand, KROMASURE™ InSite, and KROMASURE™ PinPoint.
KromaTiD has 4 investors. Key investors include HHS, Broadoak Capital Partners, NHGRI, and First Capital Ventures.